4.6.2 Migraine and Headache
NHS Kent & Medway guidance on the use of Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults. Please Click Here
Migraines and Headaches - Management of Adults with Headaches and Migraines in Primary Care Guidance and Migraine referral Form Click Here
Topiramate - Topiramate is contraindicated in pregnancy and in women of childbearing potential unless the conditions of a Pregnancy Prevention Programme are fulfilled. For Implementing MHRA Safety Measures in Kent & Medway Click Here
Rimegepant in Acute Migraine
For Kent and Medway Rimegepant Prescribing Guideline for Primary Care Click Here
Erenumab (Aimovig®) |
This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA682 |
For more information and NICE Guidance Click Here | Erenumab for preventing migraine NICE Guidance TA682 ICB commissioned - approval via Blueteq |
|
This High-Cost Drug has been approved for the following indications: - for for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA871 |
For more information and NICE Guidance Click Here | Eptinezumab for preventing migraine NICE Guidance TA871 ICB commissioned - approval via Blueteq |
Fremanezumab (Ajovy®) |
This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA764 |
For more information and NICE Guidance Click Here | Fremanezumab for preventing migraine NICE Guidance TA764 ICB commissioned - approval via Blueteq |
|
This High-Cost Drug has been approved for the following indications: - for for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA659 |
For more information and NICE Guidance Click Here | Galcanezumab for preventing migraine NICE Guidance TA659 ICB commissioned - approval via Blueteq |
|
This Drug has been approved for the following indications: - for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA906 -Acute treatment of migraine with or without aura in adults as per NICE TA919 |
For more information and NICE Guidance Click Here |
Rimegepant for preventing migraine NICE Guidance TA906 ICB commissioned - approval via Blueteq |
Pack |
---|
12 tablet |
2 tablet |
4 tablet |
6 tablet |
Pack |
---|
12 tablet |
2 tablet |
4 tablet |
6 tablet |
Pack |
---|
2 unit dose |
Pack |
---|
2 unit dose |
6 unit dose |
Pack |
---|
2 pre-filled disposable injection |
Pack |
---|
28 tablet |
60 tablet |
84 tablet |
Pack |
---|
28 tablet |
On formulary for the acute treatment of migraine in adults in accordance with NICE TA919. The Kent and Medway guidelines on the Management of Adults with Headaches and Migraines in Primary Care will be updated in due course, use local Advice and Guidance in the interim.
For Rimegepant Prescribing Guideline for Primary Care & NICE TA919 Click Here
Rimegepant for Acute treatment of migraine with or without aura in adults as per NICE Guidance TA919
Pack |
---|
2 tablet |
8 tablet |
Pack |
---|
3 tablet |
6 tablet |
Pack |
---|
12 tablet |
2 tablet |
3 tablet |
6 tablet |
Pack |
---|
3 tablet |
6 tablet |
Pack |
---|
3 tablet |
6 tablet |
Pack |
---|
6 unit dose |
Pack |
---|
6 tablet |
Pack |
---|
12 tablet |
6 tablet |
Pack |
---|
6 tablet |
Pack |
---|
12 tablet |
6 tablet |
NHS Kent & Medway guidance on the use of Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults. Please Click Here
Pack |
---|
1 vial |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only